First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.
Alexis B CortotAnne MadroszykEtienne Giroux-LeprieurOlivier MolinierElisabeth QuoixHenri BérardJosiane OttoIsabelle RaultDenis Moro-SibilotJudith RaimbourgElodie AmourFranck MorinJosé HureauxLionel MoreauDidier DebieuvreHugues MorelAldo RenaultEric PichonBenjamin HuretSandrine CharpentierMarc Guillaume DenisJacques CadranelPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These results suggest that addition of cetuximab to afatinib does not warrant further investigation in treatment-naïve advanced EGFR-mutant NSCLC.
Keyphrases
- phase ii
- epidermal growth factor receptor
- small cell lung cancer
- wild type
- open label
- advanced non small cell lung cancer
- clinical trial
- tyrosine kinase
- double blind
- placebo controlled
- phase iii
- metastatic colorectal cancer
- locally advanced
- randomized controlled trial
- radiation therapy
- combination therapy
- angiotensin ii